GSK’s late entry to the vaccine race will help protect it from aggressive investors | Nils Pratley
Whatever Elliott Management’s intentions, the UK-based pharmaceutical firm will now be seen as a national asset GlaxoSmithKline’s progress on Covid vaccines has been slow, frustrating and surprising. More was expected sooner, because the company remains far bigger in the wider vaccine field than, say, AstraZeneca. But there are now tangible signs the pace is improving. […]